Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | FLT3 | P36888 | 3/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.60 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.60 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | AIP | O00170 | 1/20 | 0.56 |
| ▸ | SGTA | O43765 | 1/20 | 0.56 |
| ▸ | TOMM70 | O94826 | 1/20 | 0.56 |
| ▸ | STIP1 | P31948 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289822 | 0.85 | MAPT (0.68) | MAPTRXFP1ALDH1A1L3MBTL1DUSP3 | |
| SCHEMBL8288667 | 0.84 | MAPT (1.00) | MAPTRXFP1ALDH1A1L3MBTL1DUSP3 | |
| SCHEMBL13574989 | 0.83 | MAPT (0.72) | MAPTRXFP1ALDH1A1L3MBTL1DUSP3 | |
| SCHEMBL21045428 | 0.83 | FLT3 (0.95) | MAPTFLT3RXFP1ALDH1A1L3MBTL1 | |
| SCHEMBL8290726 | 0.83 | FLT3 (1.00) | MAPTFLT3RXFP1ALDH1A1L3MBTL1 | |
| SCHEMBL12632694 | 0.82 | FLT3 (0.98) | MAPTFLT3RXFP1ALDH1A1L3MBTL1 | |
| SCHEMBL2182372 | 0.82 | TP53 (0.80) | MAPTFLT3ALDH1A1L3MBTL1DUSP3 | |
| SCHEMBL8290418 | 0.81 | MAPT (0.65) | MAPTRXFP1ALDH1A1L3MBTL1DUSP3 | |
| SCHEMBL8289514 | 0.81 | AIP (0.69) | MAPTRXFP1ALDH1A1L3MBTL1DUSP3 | |
| SCHEMBL8290636 | 0.80 | MAPT (0.64) | MAPTRXFP1ALDH1A1L3MBTL1DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | claimed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| EP-1492783-A1 | 4,5,6,7-TRETRAHYDROBENZO(B) THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | Axxima Pharmaceuticals AG (DE) | 2005-01-05 | — | — | EP | claimed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | claimed |
| WO-2003084947-A1 | 4,5,6,7-TRETRAHYDROBENZO[B] THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-16 | — | — | WO | claimed |
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PATO JANOS | 2009-12-03 | — | — | US | disclosed |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | AXXIMA PHARMACEUTICALS AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| EP-1492783-A1 | 4,5,6,7-TRETRAHYDROBENZO(B) THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | Axxima Pharmaceuticals AG (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | VICHEM CHEMIE KFT (HU) | 2004-09-02 | — | — | US | disclosed |
| WO-2003084947-A1 | 4,5,6,7-TRETRAHYDROBENZO[B] THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS | AXXIMA PHARMACEUTICALS AG (DE) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298842-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, MASTL, BPGM | MAPT 3062/4885FLT3 1858/4885RXFP1 2550/4885 |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | MAPT 21/4885FLT3 3509/4885RXFP1 4595/4885 |
| US-20040171603-A1 | Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor | PKLR, PKN1, PKMYT1 | MAPT 2046/4885FLT3 1906/4885RXFP1 2697/4885 |
| US-20090018149-A1 | 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections | STK4, SBK3, STK17B | MAPT 2119/4885FLT3 832/4885RXFP1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.